Shrunk NSAIDs market led by domestic drugs
The domestic osteoarthritis treatment market led by Pfizer Pharmaceuticals Korea’s ‘Celebrex’ has quickly been depressed.
The patent expiration of the leading product, Celebrex, and the increased prescriptions of NSAIDs+PPI complexes were analyzed as the main causes of the phenomenon.
According...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
